Pre-Made Retlirafusp Alfa Biosimilar, Fusion Protein targeting CD274/PD-L1 fused with human TGFBR2 (transforming growth factor beta receptor 2) extracellular fragment (20-136) via a peptidyl linker: Recombinant therapeutic protein targeting B7-H/B7H1/PDCD1L1/PDCD1LG1 for drug discovery and mechanism of action (MOA) research

Pre-Made Retlirafusp Alfa Biosimilar, Fusion Protein targeting CD274/PD-L1 fused with human TGFBR2 (transforming growth factor beta receptor 2) extracellular fragment (20-136) via a peptidyl linker: Recombinant therapeutic protein targeting B7-H/B7H1/PDCD1L1/PDCD1LG1 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Retlirafusp alfa is a novel bifunctional fusion protein composed of a mAb against PD-L1 fused with the extracellular domain of TGF-b receptor II. Retlirafusp alfa target programmed cell death ligand-1 (PDL-1) and transforming growth factor-β (TGF-β) and exhibits antitumor activity.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-972-1mg	1mg	3090
GMP-Bios-INN-972-10mg	10mg	Inquiry
GMP-Bios-INN-972-100mg	100mg	Inquiry
GMP-Bios-INN-972-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Retlirafusp Alfa Biosimilar, Fusion Protein targeting CD274/PD-L1 fused with human TGFBR2 (transforming growth factor beta receptor 2) extracellular fragment (20-136) via a peptidyl linker: Recombinant therapeutic protein targeting B7-H/B7H1/PDCD1L1/PDCD1LG1
INN Name	Retlirafusp Alfa
Target	CD274/PD-L1
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	IgG4 - kappa
VD LC	IgG4 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang Jiangsu China)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0